Cannabis and development of dual diagnoses: A literature review

References

• Substance Abuse Mental Health Services Administration (SAMHSA). Available from: http://www.samhsa.gov/data/[last accessed 15 January 2016]
   Google Scholar
• Johnston LD, Miech RA, O’Malley PM, Bachman JG, Schulenberg JE. Use of ecstasy, heroin, synthetic marijuana, alcohol, cigarettes declined among US teens in 2015. Available from: http://www.monitoringthefuture.org [last accessed 15 January 2016].
   Google Scholar
• van Os J, et al. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002;156:319–327.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin JB, Hall WD, Patton GC. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction 2013;108:124–133.
   PubMed Web of Science ®Google Scholar
• Negrete JC. Relative value of various etiological factors in short lasting, adverse psychological reactions to cannabis smoking. Br J Addict Alcohol Other Drugs 1973;68:221–229.
   PubMedGoogle Scholar
• Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. Addiction 1998;93:837–846.
   PubMed Web of Science ®Google Scholar
• Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 2003;22:453–460.
   PubMed Web of Science ®Google Scholar
• Green B, Kavanagh DJ, Young RM, Reasons for cannabis use in men with and without psychosis. Drug Alcohol Rev 2004;23:445–453.
   PubMed Web of Science ®Google Scholar
• Mane A, Fernandez-Exposito M, Berge D, Gomez-Perez L, Sabate A, Toll A, Diaz L, et al. Relationship between cannabis and psychosis: reasons for use and associated clinical variables. Psychiatry Res 2015;229:70–74.
   PubMed Web of Science ®Google Scholar
• Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001;178:116–122.
   PubMed Web of Science ®Google Scholar
• Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry 1993;163:141–149.
   PubMed Web of Science ®Google Scholar
• Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend 1996;42:201–207.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan R, Wilkinson ST, D’Souza DC. Gone to pot – a review of the association between cannabis and psychosis. Front Psychiatry 2014;5:54.
   PubMed Web of Science ®Google Scholar
• Crippa JA, Zuardi AW, Martin-Santos R, Bhattacharyya S, Atakan Z, McGuire P, Fusar-Poli P. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 2009;24:515–523.
   PubMed Web of Science ®Google Scholar
• Verdoux H. Gindre C, Sorbara F, Tournier M, Swendsen JD. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med 2003;33:23–32.
   PubMed Web of Science ®Google Scholar
• Henquet C, van Os J, Kuepper R, Delespaul P, Smits M, Campo JA, Myin-Germeys I. Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry 2010;196:447–453.
   PubMed Web of Science ®Google Scholar
• Mason O, Morgan CJ, Dhiman SK, Patel A, Parti N, Patel A, Curran HV. Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. Psychol Med 2009;39:951–956.
   PubMed Web of Science ®Google Scholar
• Ames F. A clinical and metabolic study of acute intoxication with Cannabis sativa and its role in the model psychoses. J Ment Sci 1958;104:972–999.
   PubMed Web of Science ®Google Scholar
• Isbell H, Jasinski DR. A comparison of LSD-25 with (-)-delta-9-trans-tetrahydrocannabinol (THC) and attempted cross tolerance between LSD and THC. Psychopharmacologia 1969;14:115–123.
   PubMed Web of Science ®Google Scholar
• Melges FT, Tinklenberg JR, Deardorff CM, Davies NH, Anderson RE, Owen CA. Temporal disorganization and delusional-like ideation. Processes induced by hashish and alcohol. Arch Gen Psychiatry 1974;30:855–861.
   PubMed Web of Science ®Google Scholar
• Melges FT. Tracking difficulties and paranoid ideation during hashish and alcohol intoxication. Am J Psychiatry 1976;133:1024–1028.
   PubMed Web of Science ®Google Scholar
• Jones RT, Stone GC. Psychological studies of marijuana and alcohol in man. Psychopharmacologia 1970;18:108–117.
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsycho-pharmacology 2004;29:1558–1572.
   PubMed Web of Science ®Google Scholar
• Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, Murray RM. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 2009;39:1607–1616.
   Web of Science ®Google Scholar
• Morrison PD, Stone JM. Synthetic delta-9-tetrahydroca-nnabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. Hum Psychopharmacol 2011;26:77–80.
   PubMed Web of Science ®Google Scholar
• Morrison PD, Nottage J, Stone JM, Bhattacharyya S, Tunstall N, Brenneisen R, Holt D, et al. Disruption of frontal theta coherence by Delta9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology 2011;36:827–836.
   PubMed Web of Science ®Google Scholar
• Freeman D, Dunn G, Murray RM, Evans N, Lister R, Antley A, Slater M, et al. How cannabis causes paranoia: using the intravenous administration of 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull 2015;41:391–399.
   PubMed Web of Science ®Google Scholar
• Martin-Santos R, Crippa JA, Batallla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 2012;18:4966–4979.
   PubMed Web of Science ®Google Scholar
• Curran HV, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) 2002;164:61–70.
   PubMed Web of Science ®Google Scholar
• Koethe D, Gerth CW, Neatby MA, Haensel A, Thies M, Schneider U, Emrich HM, et al. Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr Res 2006;88:142–150.
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology, 2008;33:2505–2516.
   PubMed Web of Science ®Google Scholar
• Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 2009;23:266–277.
   PubMed Web of Science ®Google Scholar
• Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, et al. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology (Berl) 2013;226:401–413.
   PubMed Web of Science ®Google Scholar
• Negrete JC. Psychological adverse effects of cannabis smoking: a tentative classification. Canadian Med Assoc J 1973;108:195–202.
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005;57:594–608.
   PubMed Web of Science ®Google Scholar
• Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005;81:331–342.
   PubMed Web of Science ®Google Scholar
• Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 2015;162:153–161.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008;192:306–307.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry 2010;197:285–290.
   PubMed Web of Science ®Google Scholar
• Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol 1974;28:172–177.
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982;76:245–250.
   PubMed Web of Science ®Google Scholar
• Dalton WS, et al. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 1976;19:300–309.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010;35:764–774.
   PubMed Web of Science ®Google Scholar
• Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013;27:19–27.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav 2000;66:175–181.
   PubMed Web of Science ®Google Scholar
• Papanti D, Schifano F, Botteon G, Bertossi F, Mannix J, Vidoni D, Impagnatiello M, et al. “Spiceophrenia”: a systematic overview of “spice”-related psychopathological issues and a case report. Hum Psychopharmacol 2013;28:379–389.
   PubMed Web of Science ®Google Scholar
• Dekker N, Linszen DH, De Haan L. Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology 2009;42:350–360.
   PubMed Web of Science ®Google Scholar
• Negrete JC, Knapp WP. The effects of cannabis use on the clinical condition of schizophrenics. NIDA Res Monogr 1986;67:321–327.
   PubMedGoogle Scholar
• Lindemann E, Malamud W. Experimental analysis of the psychopathological effects of intoxicating drugs. American Journal of Psychiatry 1934;90:853–881.
   Google Scholar
• Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, Ramaekers JG, van Os J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006;31:2748–2757.
   PubMed Web of Science ®Google Scholar
• Anthony JC. The epidemiology of cannabis dependence. In: Roffman RA, Stephens RS, eds. Cannabis dependence: its nature, consequences and treatment. Cambridge, UK: Cambridge University Press; 2006:58–105
   Google Scholar
• Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014;371:879.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Neale MC, Prescott CA, Kendler KS. Cannabis and other illicit drugs: comorbid use and abuse/dependence in males and females. Behav Genet 2004;34:217–228.
   PubMed Web of Science ®Google Scholar
• Fergusson DM, Horwood LJ. Does cannabis use encourage other forms of illicit drug use? Addiction 2000;95:505–520.
   PubMed Web of Science ®Google Scholar
• Khan SS, Secades-Villa R, Okuda M, Wang S, Perez-Fuentes G, Kerridge BT, Blanco C. Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions. Drug Alcohol Depend 2013;130:101–108.
   PubMed Web of Science ®Google Scholar
• Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PA, Nelson EC, Statham DJ, Martin NG. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA 2003;289:427–433.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Lupi M, Carlucci L, Cinosi E, Santacroce R, Acciavatti T, Chillemi E, et al. Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas. Hum Psychopharmacol 2015;30:295–301.
   PubMed Web of Science ®Google Scholar
• Bersani FS, Corazza O, Albano G, Valeriani G, Santacroce R, Bolzan Mariotti Posocco F, et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res Int 2014;2014:734749.
   PubMed Web of Science ®Google Scholar
• Schifano F, Deluca P, Agosti L, Martinotti G, Corkery JM, Alex B, Caterina B, et al. New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 (‘Blue Mystic’). J Psychopharmacol 2005;19:675–679.
   PubMed Web of Science ®Google Scholar
• Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction 2006;101:556–569.
   PubMed Web of Science ®Google Scholar
• Golub A, Johnson BD. The shifting importance of alcohol and marijuana as gateway substances among serious drug abusers. J Stud Alcohol 1994;55:607–614.
   PubMed Web of Science ®Google Scholar
• Kandel DB, Yamaguchi K, Chen K. Stages of progression in drug involvement from adolescence to adulthood: further evidence for the gateway theory. J Stud Alcohol 1992;53:447–457.
   PubMed Web of Science ®Google Scholar
• Swift W, Coffey C, Degenhardt L, Carlin JB, Romaniuk H, Patton GC. Cannabis and progression to other substance use in young adults: findings from a 13-year prospective population-based study. J Epidemiol Community Health 2012;66:e26.
   PubMed Web of Science ®Google Scholar
• Secades-Villa R, Garcia-Rodriguez O, Jin CJ, Wang S, Blanco C. Probability and predictors of the cannabis gateway effect: a national study. Int J Drug Policy 2015;26:135–142.
   PubMed Web of Science ®Google Scholar
• Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, Spry E, et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry 2014;1:286–293.
   PubMed Web of Science ®Google Scholar
• Chopra GS. Studies on psycho-clinical aspects of long-term marihuana use in 124 cases. Int J Addict 1973;8:1015–1026.
   PubMed Web of Science ®Google Scholar
• Basu D, Malhotra A, Bhagat A, Varma VK. Cannabis psychosis and acute schizophrenia. a case-control study from India. Eur Addict Res 1999;5:71–73.
   PubMed Web of Science ®Google Scholar
• Thacore VR. Bhang psychosis. Br J Psychiatry 1973;123:225–229.
   PubMed Web of Science ®Google Scholar
• Baker AA, Lucas EG. Some hospital admissions associated with cannabis. Lancet 1969;1:148.
   PubMed Web of Science ®Google Scholar
• Retterstol N. Cannabis-psychoses. 46 cases reported from Sweden. Tidsskr Nor Laegeforen 1973;93:1410.
   Google Scholar
• Defer B, Diehl ML. Acute psychoses due to cannabis (apropos of 560 cases). Ann Med Psychol (Paris) 1968;2:260–266.
   PubMedGoogle Scholar
• Wilkinson ST, Radhakrishnan R, D’Souza DC. Impact of cannabis use on the development of psychotic disorders. Curr Addict Rep 2014;1:115–128.
   PubMedGoogle Scholar
• Talbott JA, Teague JW. Marihuana psychosis. Acute toxic psychosis associated with the use of cannabis derivatives. JAMA 1969;210:299–302.
   Google Scholar
• Niemi-Pynttari JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry 2013;74:e94–e99.
   PubMed Web of Science ®Google Scholar
• Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry 2005;187:510–515.
   PubMed Web of Science ®Google Scholar
• Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 2010;36:1115–1130.
   PubMed Web of Science ®Google Scholar
• Loberg EM, Helle S, Nygard M, Berle JO, Kroken RA, Johnsen E. The cannabis pathway to non-affective psychosis may reflect less neurobiological vulnerability. Front Psychiatry 2014;5:159.
   PubMed Web of Science ®Google Scholar
• Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry 2015.
   Google Scholar
• Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ, 2002;325:1212–1213.
   PubMed Web of Science ®Google Scholar
• Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002;325:1199.
   PubMed Web of Science ®Google Scholar
• Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005;19:187–194.
   PubMed Web of Science ®Google Scholar
• Compton MT, et al., Kelley ME, Ramsay CE, Pringle M, Goulding SM, Esterberg ML, Stewart T, Walker EF. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry 2009;166:1251–1257.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Pinto A, Vega P, Ibanez B, Mosquera F, Barbeito S, Gutierrez M, Ruiz de Azua S, et al. Impact of cannabis and other drugs on age at onset of psychosis. J Clin Psychiatry 2008;69:1210–1216.
   PubMed Web of Science ®Google Scholar
• Leeson VC, Harrison I, Ron MA, Barnes TR, Joyce EM. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr Bull 2012;38:873–880.
   PubMed Web of Science ®Google Scholar
• Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA. Age at initiation of cannabis use predicts age at onset of psychosis: the 7- to 8-year trend. Schizophr Bull 2013;39:251–254.
   PubMed Web of Science ®Google Scholar
• Tosato S, Lasalvia A, Bonetto C, Mazzoncini R, Cristofalo D, De Santi K, Bertani M, et al. The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). J Psychiatr Res, 2013;47:438–444.
   Google Scholar
• Sevy S, Robinson DG, Napolitano B, Patel RC, Gunduz-Bruce H, Miller R, McCormack J, et al. Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. Schizophr Res 2010;120:101–107.
   PubMed Web of Science ®Google Scholar
• Schimmelmann BG, Conus P, Cotton SM, Kupferschmid S, Karow A, Schultze-Lutter F, McGorry PD, Lambert M. Cannabis use disorder and age at onset of psychosis–a study in first-episode patients. Schizophr Res 2011;129:52–56.
   PubMed Web of Science ®Google Scholar
• Allegri F, Belvederi Murri M, Paparelli A, Marcacci T, Braca M, Menchetti M, Michetti R, et al. Current cannabis use and age of psychosis onset: a gender-mediated relationship? Results from an 8-year FEP incidence study in Bologna. Psychiatry Res 2013;210:368–370.
   PubMed Web of Science ®Google Scholar
• Estrada G, Fatjo-Vilas M, Munoz MJ, Pulido G, Minano MJ, Toledo E, Illa JM, et al. Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism. Acta Psychiatr Scand 2011;123:485–492.
   PubMed Web of Science ®Google Scholar
• Myles H, Myles N, Large M. Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Aust N Z J Psychiatry 2006; 50:208–219.
   Google Scholar
• Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 2011;68:555–561.
   PubMed Web of Science ®Google Scholar
• Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 2014;40:1509–1517.
   PubMed Web of Science ®Google Scholar
• Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330:11.
   PubMed Web of Science ®Google Scholar
• Kraan T, Velthorst E, Koenders L, Zwaart K, Ising HK, van den Berg D, de Haan L, van der Gaag M. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. Psychol Med 2015:1–9.
   Web of Science ®Google Scholar
• Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005;100:612–618.
   PubMed Web of Science ®Google Scholar
• Griffith-Lendering MF, Wigman JT, Prince van Leeuwen A, Huijbregts SC, Huizink AC, Ormel J, Verhulst FC, et al. Cannabis use and vulnerability for psychosis in early adolescence–a TRAILS study. Addiction 2013;108:733–740.
   PubMed Web of Science ®Google Scholar
• Dubowitz H, et al., Thompson R, Arria AM, English D, Metzger R, Kotch JB. Characteristics of child maltreatment and adolescent marijuana use: a prospective study. Child Maltreat 2016;21:16–25.
   PubMed Web of Science ®Google Scholar
• Harley M, Kelleher I, Clarke M, Lynch F, Arseneault L, Connor D, Fitzpatrick C, Cannon M. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol Med 2010;40:1627–1634.
   PubMed Web of Science ®Google Scholar
• Houston JE, Murphy J, Adamson G, Stringer M, Shevlin M. Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr Bull 2008;34:580–585.
   PubMed Web of Science ®Google Scholar
• Konings M, Stefanis N, Kuepper R, de Graaf R, ten Have M, van Os J, Bakoula C, Henquet C. Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol Med 2012;42:149–159.
   PubMed Web of Science ®Google Scholar
• Stirling J, et al., Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res 2005;75:135–137.
   PubMed Web of Science ®Google Scholar
• Jockers-Scherubl MC, Wolf T, Radzei N, Schlattmann P, Rentzsch J, Gomez-Carrillo de Castro A, Kuhl KP. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1054–1063.
   PubMed Web of Science ®Google Scholar
• Schnell T, Koethe D, Daumann J, Gouzoulis-Mayfrank E. The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berl) 2009;205:45–52.
   PubMed Web of Science ®Google Scholar
• Yucel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 2012;38:316–330.
   PubMed Web of Science ®Google Scholar
• Loberg EM, Hugdahl K. Cannabis use and cognition in schizophrenia. Front Hum Neurosci 2009;3:53.
   PubMed Web of Science ®Google Scholar
• Kumra S, Thaden E, DeThomas C, Kranzler H. Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and schizoaffective disorder. Schizophr Res 2005;73:369–371.
   PubMed Web of Science ®Google Scholar
• de la Serna E, Mayoral M, Baeza I, Arango C, Andres P, Bombin I, Gonzalez C, et al. Cognitive functioning in children and adolescents in their first episode of psychosis: differences between previous cannabis users and nonusers. J Nerv Ment Dis 2010;198:159–162.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Sanchez JM, Ayesa-Arriola R, Mata I, Moreno-Calle T, Perez-Iglesias R, Gonzalez-Blanch C, Perianez JA, et al. Cannabis use and cognitive functioning in first-episode schizophrenia patients. Schizophr Res 2010;124:142–151.
   PubMed Web of Science ®Google Scholar
• Sevy, S., Burdick KE, Visweswaraiah H, Abdelmessih S, Lukin M, Yechiam E, Bechara A. Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr Res 2007;92:74–84.
   PubMed Web of Science ®Google Scholar
• DeRosse P, Kaplan A, Burdick KE, Lencz T, Malhotra AK. Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr Res 2010;120:95–100.
   PubMed Web of Science ®Google Scholar
• Meijer JH, Dekker N, Koeter MW, Quee PJ, van Beveren NJ, Meijer CJ. Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. Psychol Med 2012;42:705–716.
   PubMed Web of Science ®Google Scholar
• Coulston CM, Perdices M, Tennant CC. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophr Res 2007;96:169–184.
   PubMed Web of Science ®Google Scholar
• Cunha PJ, Rosa PG, Ayres Ade M, Duran FL, Santos LC, Scazufca M, Menezes PR, et al. Cannabis use, cognition and brain structure in first-episode psychosis. Schizophr Res 2013;147:209–215.
   PubMed Web of Science ®Google Scholar
• Nunez C, Ochoa S, Huerta-Ramos E, Banos I, Barajas A, Dolz M, Sanchez B, et al. Cannabis use and cognitive function in first episode psychosis: differential effect of heavy use. Psychopharmacology (Berl) 2016: 233:809–821.
   Google Scholar
• Hanna RC, Shalvoy A, Cullum CM, Ivleva EI, Keshavan M, Pearlson G, Hill SK, et al. Cognitive function in individuals with psychosis: moderation by adolescent cannabis use. Schizophr Bull 2016 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Mata I, Rodriguez-Sanchez JM, Pelayo-Teran JM, Perez-Iglesias R, Gonzalez-Blanch C, Ramirez-Bonilla M, Martinez-Garcia O, et al. Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. Psychol Med 2008;38:1257–1266.
   PubMed Web of Science ®Google Scholar
• Power BD, Dragovic M, Badcock JC, Morgan VA, Castle D, Jablensky A, Stefanis NC. No additive effect of cannabis on cognition in schizophrenia. Schizophr Res, 2015;168:245–251.
   PubMed Web of Science ®Google Scholar
• Ringen PA, Vaskinn A, Sundet K, Engh JA, Jonsdottir H, Simonsen C, Friis S, et al. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychol Med 2010;40:1337–1347.
   PubMed Web of Science ®Google Scholar
• Schoeler T, Kambeitz J, Behlke I, Murray R, Bhattacharyya S. The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis. Psychol Med 2016;46:177–188.
   PubMed Web of Science ®Google Scholar
• Rabin RA, Zakzanis KK, George TP. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res 2011;128:111–116.
   PubMed Web of Science ®Google Scholar
• de la Serna E, Mayoral M, Baeza I, Arango C, Andres P, Bombin I, Gonzalez C, et al. Cognitive functioning in children and adolescents in their first episode of psychosis: differences between previous cannabis users and nonusers. J Nerv Ment Dis;198:159–162.
   PubMed Web of Science ®Google Scholar
• Epstein KA, Kumra S. Executive attention impairment in adolescents with schizophrenia who have used cannabis. Schizophr Res 2014;157:48–54.
   PubMed Web of Science ®Google Scholar
• Yucel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 2012; 38:316–330.
   Google Scholar
• Lisdahl KM, Gilbart ER, Wright NE, Shollenbarger S. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry 2013;4:53.
   PubMedGoogle Scholar
• Tapert SF, Granholm E, Leedy NG, Brown SA. Substance use and withdrawal: neuropsychological functioning over 8 years in youth. J Int Neuropsychol Soc 2002;8:873–883.
   PubMed Web of Science ®Google Scholar
• Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 2012;109:E2657–E2664.
   PubMed Web of Science ®Google Scholar
• Chen CY, Wagner FA, Anthony JC. Marijuana use and the risk of Major Depressive Episode. Epidemiological evidence from the United States National Comorbidity Survey. Soc Psychiatry Psychiatr Epidemiol 2002;37:199–206.
   PubMed Web of Science ®Google Scholar
• Fairman BJ, Anthony JC. Are early-onset cannabis smokers at an increased risk of depression spells? J Affect Disord 2012;138:54–62.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. Addiction, 2003;98:1493–1504.
   PubMed Web of Science ®Google Scholar
• Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med 2014;44:797–810.
   PubMed Web of Science ®Google Scholar
• Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319–328.
   PubMed Web of Science ®Google Scholar
• Pacek LR, Martins SS, Crum RM. The bidirectional relationships between alcohol, cannabis, co-occurring alcohol and cannabis use disorders with major depressive disorder: results from a national sample. J Affect Disord 2013;148:188–195.
   PubMed Web of Science ®Google Scholar
• Feingold D, Weiser M, Rehm J, Lev-Ran S. The association between cannabis use and mood disorders: A longitudinal study. J Affect Disord 2014;172C:211–218.
   Google Scholar
• Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001;158:2033–2037.
   PubMed Web of Science ®Google Scholar
• Brook DW, Brook JS, Zhang C, Cohen P, Whiteman M. Drug use and the risk of major depressive disorder, alcohol dependence, and substance use disorders. Arch Gen Psychiatry 2002;59:1039–1044.
   PubMed Web of Science ®Google Scholar
• Fergusson DM, Horwood LJ, Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 2002;97:1123–1135.
   PubMed Web of Science ®Google Scholar
• Marmorstein NR, Iacono WG. Explaining associations between cannabis use disorders in adolescence and later major depression: a test of the psychosocial failure model. Addict Behav 2011;36:773–776.
   PubMed Web of Science ®Google Scholar
• Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ 2002;325:1195–1198.
   PubMed Web of Science ®Google Scholar
• Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W. Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry 2007;46:408–417.
   PubMed Web of Science ®Google Scholar
• Rey JM, Sawyer MG, Raphael B, Patton GC, Lynskey M. Mental health of teenagers who use cannabis. Results of an Australian survey. Br J Psychiatry 2002;180:216–221.
   Google Scholar
• van Laar M, van Dorsselaer S, Monshouwer K, de Graaf R. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction 2007;102:1251–1260.
   PubMed Web of Science ®Google Scholar
• Fergusson DM, Horwood LJ. Early onset cannabis use and psychosocial adjustment in young adults. Addiction 1997;92:279–296.
   PubMed Web of Science ®Google Scholar
• Harder VS, Stuart EA, Anthony JC. Adolescent cannabis problems and young adult depression: male-female stratified propensity score analyses. Am J Epidemiol 2008;168:592–601.
   PubMed Web of Science ®Google Scholar
• Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Allebeck P. Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts. BMC Psychiatry 2012;12:112.
   PubMed Web of Science ®Google Scholar
• Windle M, Wiesner M. Trajectories of marijuana use from adolescence to young adulthood: predictors and outcomes. Dev Psychopathol 2004;16:1007–1027.
   PubMed Web of Science ®Google Scholar
• de Graaf R, Radovanovic M, van Laar M, Fairman B, Degenhardt L, Aguilar-Gaxiola S, Bruffaerts R, et al. Early cannabis use and estimated risk of later onset of depression spells: epidemiologic evidence from the population-based World Health Organization World Mental Health Survey Initiative. Am J Epidemiol 2010;172:149–159.
   PubMed Web of Science ®Google Scholar
• Pedersen W. Does cannabis use lead to depression and suicidal behaviours? A population-based longitudinal study. Acta Psychiatr Scand 2008;118:395–403.
   PubMed Web of Science ®Google Scholar
• Lynskey MT, Glowinski AL, Todorov AA, Bucholz KK, Madden PA, Nelson EC, Statham DJ, et al. Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch Gen Psychiatry 2004; 61:1026–1032.
   PubMed Web of Science ®Google Scholar
• Lai HM, Sitharthan T. Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. Am J Drug Alcohol Abuse 2012;38:567–574.
   PubMed Web of Science ®Google Scholar
• Crane NA, Langenecker SA, Mermelstein RJ. Gender differences in the associations among marijuana use, cigarette use, and symptoms of depression during adolescence and young adulthood. Addict Behav 2015;49:33–39.
   PubMed Web of Science ®Google Scholar
• Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord 2001;3:181–188.
   PubMed Web of Science ®Google Scholar
• Sherwood Brown E, Suppes T, Adinoff B, Rajan Thomas N. Drug abuse and bipolar disorder: comorbidity or misdiagnosis? J Affect Disord 2001;65:105–115.
   PubMed Web of Science ®Google Scholar
• Lev-Ran S, S, Le Foll B, McKenzie K, George TP, Rehm J. Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. Psychiatry Res 2013;209:459–465.
   PubMed Web of Science ®Google Scholar
• Bally N, Zullino D, Aubry JM. Cannabis use and first manic episode. J Affect Disord 2014;165:103–108.
   PubMed Web of Science ®Google Scholar
• Cerullo MA, Strakowski SM. The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy 2007;2:29.
   PubMed Web of Science ®Google Scholar
• Etain B, Lajnef M, Bellivier F, Mathieu F, Raust A, Cochet B, Gard S, et al. Clinical expression of bipolar disorder type I as a function of age and polarity at onset: convergent findings in samples from France and the United States. J Clin Psychiatry 2012;73:e561–566.
   PubMedGoogle Scholar
• Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J. Cannabis use and expression of mania in the general population. J Affect Disord 2006;95:103–110.
   PubMed Web of Science ®Google Scholar
• Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord 2015;171:39–47.
   PubMed Web of Science ®Google Scholar
• Cougle JR, Hakes JK, Macatee RJ, Chavarria J, Zvolensky MJ. Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: an analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Psychiatr Res 2015;66–67:135–141.
   PubMed Web of Science ®Google Scholar
• Feinman JA, Dunner DL. The effect of alcohol and substance abuse on the course of bipolar affective disorder. J Affect Disord 1996;37:43–49.
   PubMed Web of Science ®Google Scholar
• Fossey MD, Otto MW, Yates WR, Wisniewski SR, Gyulai L, Allen MH, Miklowitz DJ, et al. Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: data from the first 1000 STEP-BD participants. Am J Addict 2006;15:138–143.
   PubMed Web of Science ®Google Scholar
• Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE, Jr., Arnold LM, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry 2007;64:57–64.
   PubMed Web of Science ®Google Scholar
• Lagerberg TV, Sundet K, Aminoff SR, Berg AO, Ringen PA, Andreassen OA, Melle I. Excessive cannabis use is associated with earlier age at onset in bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2011;261:397–405.
   PubMed Web of Science ®Google Scholar
• Kvitland LR, Melle I, Aminoff SR, Lagerberg TV, Andreassen OA, Ringen PA. Cannabis use in first-treatment bipolar I disorder: relations to clinical characteristics. Early Interv Psychiatry 2016;10:36–44.
   PubMed Web of Science ®Google Scholar
• De Hert M, Wampers M, Jendricko T, Franic T, Vidovic D, De Vriendt N, Sweers K, et al. Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. Schizophr Res 2011;126:270–276.
   PubMed Web of Science ®Google Scholar
• Lagerberg TV, Kvitland LR, Aminoff SR, Aas M, Ringen PA, Andreassen OA, Melle I. Indications of a dose-response relationship between cannabis use and age at onset in bipolar disorder. Psychiatry Res 2014;215:101–104.
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Herrell R, Swendsen J, Rossler W, Ajdacic-Gross V, Angst J. Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders: results from the Zurich cohort study. Arch Gen Psychiatry 2008;65:47–52.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Nurnberger JI, Jr., Lynskey MT, Bipolar Genome S. Cannabis involvement in individuals with bipolar disorder. Psychiatry Res 2011;185:459–461.
   PubMed Web of Science ®Google Scholar
• Wilens TE, Biederman J, Millstein RB, Wozniak J, Hahesy AL, Spencer TJ. Risk for substance use disorders in youths with child- and adolescent-onset bipolar disorder. J Am Acad Child Adolesc Psychiatry 1999;38:680–685.
   PubMed Web of Science ®Google Scholar
• Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs 1998;30:171–177.
   PubMed Web of Science ®Google Scholar
• Healey C, Peters S, Kinderman P, McCracken C, Morriss R. Reasons for substance use in dual diagnosis bipolar disorder and substance use disorders: a qualitative study. J Affect Disord 2009;113:118–126.
   PubMed Web of Science ®Google Scholar
• Tyler E, Jones S, Black N, Carter LA, Barrowclough C. The relationship between bipolar disorder and cannabis use in daily life: an experience sampling study. PLoS One 2015;10:e0118916.
   PubMed Web of Science ®Google Scholar
• Duffy A, Horrocks J, Milin R, Doucette S, Persson G, Grof P. Adolescent substance use disorder during the early stages of bipolar disorder: a prospective high-risk study. J Affect Disord 2012;142:57–64.
   PubMed Web of Science ®Google Scholar
• Aas M, Etain B, Bellivier F, Henry C, Lagerberg T, Ringen A, Agartz I, et al. Additive effects of childhood abuse and cannabis abuse on clinical expressions of bipolar disorders. Psychol Med 2014;44:1653–1662.
   PubMed Web of Science ®Google Scholar
• Braga RJ, Burdick KE, Derosse P, Malhotra AK. Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Res 2012;200:242–5.
   PubMed Web of Science ®Google Scholar
• Agosti V, Nunes E, Levin F. Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse 2002;28:643–652.
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Frohlich C, Behrendt S, Gunther A, Rehm J, Zimmermann P, Lieb R, Perkonigg A. Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend 2007;88:S60–S70.
   PubMed Web of Science ®Google Scholar
• Feingold D, Weiser M, Rehm J, Lev-Ran S. The association between cannabis use and anxiety disorders: results from a population-based representative sample. Eur Neuropsychopharmacol 2016; 26:493–505.
   Google Scholar
• Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use, depression and anxiety among Australian adults: findings from the National Survey of Mental Health and Well-Being. Soc Psychiatry Psychiatr Epidemiol 2001;36:219–227.
   PubMed Web of Science ®Google Scholar
• Fergusson DM, Lynskey MT, Horwood LJ. The short-term consequences of early onset cannabis use. J Abnorm Child Psychol 1996;24:499–512.
   PubMed Web of Science ®Google Scholar
• Roberts RE, Roberts CR, Xing Y. Comorbidity of substance use disorders and other psychiatric disorders among adolescents: evidence from an epidemiologic survey. Drug Alcohol Depend 2007;88:S4–S13.
   PubMed Web of Science ®Google Scholar
• Zvolensky MJ, Cougle JR, Johnson KA, Bonn-Miller MO, Bernstein A. Marijuana use and panic psychopathology among a representative sample of adults. Exp Clin Psychopharmacol 2010;18:129–134.
   PubMed Web of Science ®Google Scholar
• Buckner JD, Schmidt NB, Bobadilla L, Taylor J. Social anxiety and problematic cannabis use: evaluating the moderating role of stress reactivity and perceived coping. Behav Res Ther 2006;44:1007–1015.
   PubMed Web of Science ®Google Scholar
• Cougle JR, Bonn-Miller MO, Vujanovic AA, Zvolensky MJ, Hawkins KA. Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychol Addict Behav 2011;25:554–558.
   PubMed Web of Science ®Google Scholar
• Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population–a meta-analysis of 31 studies. BMC Psychiatry, 2014. 14:136.
   PubMed Web of Science ®Google Scholar
• Galvez-Buccollini JA, Proal AC, Tomaselli V, Trachtenberg M, Coconcea C, Chun J, Manschreck T, et al. Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis. Schizophr Res 2012;139:157–160.
   PubMed Web of Science ®Google Scholar
• Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N, Thompson MR, et al. Adolescent rats find repeated Delta(9)- THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 2008;33:1113–1126.
   PubMed Web of Science ®Google Scholar
• O’Shea M, McGregor IS, Mallet PE. Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. J Psychopharmacol 2006;20:611–621.
   PubMed Web of Science ®Google Scholar
• O’Shea M, Singh ME, McGregor IS, Mallet PE. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol 2004;18:502–508.
   PubMed Web of Science ®Google Scholar
• Schneider M, Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 2003;28:1760–1769.
   PubMed Web of Science ®Google Scholar
• Rubino T, Parolaro D. The impact of exposure to cannabinoids in adolescence: insights from animal models. Biol Psychiatry 2016; 79:578–588
   Google Scholar
• Rubino T, Realini N, Braida D, Guidi S, Capurro V, Vigano D, Guidali C, et al. Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus 2009;19:763–772.
   PubMed Web of Science ®Google Scholar
• Rubino T, Vigano D, Realini N, Guidali C, Braida D, Capurro V, Castiglioni C, et al. Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 2008;33:2760–2771.
   PubMed Web of Science ®Google Scholar
• Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen HS, Hansen SH, Devi LA, Hurd YL. Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol 2008;18:826–834.
   PubMed Web of Science ®Google Scholar
• Higuera-Matas A, Botreau F, Del Olmo N, Miguens M, Olias O, Montoya GL, Garcia-Lecumberri C, Ambrosio E. Periadolescent exposure to cannabinoids alters the striatal and hippocampal dopaminergic system in the adult rat brain. Eur Neuropsychopharmacol 2010;20:895–906.
   PubMed Web of Science ®Google Scholar
• Burston JJ, Wiley JL, Craig AA, Selley DE, Sim-Selley LJ. Regional enhancement of cannabinoid CB₁ receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure. Br J Pharmacol 2010;161:103–112.
   PubMed Web of Science ®Google Scholar
• Gleason KA, Birnbaum SG, Shukla A, Ghose S. Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. Transl Psychiatry 2012;2:e199.
   PubMed Web of Science ®Google Scholar
• Rubino T, Guidali C, Vigano D, Realini N, Valenti M, Massi P, Parolaro D. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 2008;54:151–160.
   PubMed Web of Science ®Google Scholar
• Mateos B, Borcel E, Loriga R, Luesu W, Bini V, Llorente R, Castelli MP, Viveros MP. Adolescent exposure to nicotine and/or the cannabinoid agonist CP 55,940 induces gender-dependent long-lasting memory impairments and changes in brain nicotinic and CB(1) cannabinoid receptors. J Psychopharmacol 2011;25:1676–90.
   PubMed Web of Science ®Google Scholar
• Cass DK, Flores-Barrera E, Thomases DR, Vital WF, Caballero A, Tseng KY CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex. Mol Psychiatry 2014;19:536–543.
   PubMed Web of Science ®Google Scholar
• Zamberletti E, Beggiato S, Steardo L, Jr., Prini P, Antonelli T, Ferraro L, Rubino T, Parolaro D. Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats. Neurobiol Dis 2014;63:35–47.
   PubMed Web of Science ®Google Scholar
• Realini N, Vigano D, Guidali C, Zamberletti E, Rubino T, Parolaro D. Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats. Neuropharmacology 2011;60:235–243.
   PubMed Web of Science ®Google Scholar
• Grigorenko E, Kittler J, Clayton C, Wallace D, Zhuang S, Bridges D, Bundey S, et al. Assessment of cannabinoid induced gene changes: tolerance and neuroprotection. Chem Phys Lipids 2002;121:257–266.
   PubMed Web of Science ®Google Scholar
• Kittler JT, Grigorenko EV, Clayton C, Zhuang SY, Bundey SC, Trower MM, Wallace D, et al. Large-scale analysis of gene expression changes during acute and chronic exposure to [Delta]9-THC in rats. Physiol Genomics 2000;3:175–185.
   PubMed Web of Science ®Google Scholar
• Verweij KJ, Zietsch BP, Lynskey MT, Medland SE, Neale MC, Martin NG, Boomsma DI, Vink JM. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction 2010;105:417–430.
   PubMed Web of Science ®Google Scholar
• Lopez-Moreno JA, Echeverry-Alzate V, Buhler KM. The genetic basis of the endocannabinoid system and drug addiction in humans. J Psychopharmacol 2012;26:133–143.
   PubMed Web of Science ®Google Scholar
• Benyamina A, Kebir O, Blecha L, Reynaud M, Krebs MO. CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis. Addict Biol 2011;16:1–6.
   PubMed Web of Science ®Google Scholar
• Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE. Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. Neuropsychopharmacology 2010;35:967–975.
   PubMed Web of Science ®Google Scholar
• Schacht JP, Hutchison KE, Filbey FM. Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology 2012;37:2368–2376.
   PubMed Web of Science ®Google Scholar
• Bidwell LC, Metrik J, McGeary J, Palmer RH, Francazio S, Knopik VS. Impulsivity, variation in the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes, and marijuana-related problems. J Stud Alcohol Drugs 2013;74:867–878.
   PubMed Web of Science ®Google Scholar
• Haughey HM, Marshall E, Schacht JP, Louis A, Hutchison KE. Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction 2008;103:1678–1686.
   PubMed Web of Science ®Google Scholar
• McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 1995;15:277–281.
   PubMed Web of Science ®Google Scholar
• Genetic Risk and Outcome in Psychosis (GROUP) Investigators. Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. Arch Gen Psychiatry 2011;68:138–147.
   Google Scholar
• Arendt M, Mortensen PB, Rosenberg R, Pedersen CB, Waltoft BL. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry 2008;65:1269–1274.
   PubMed Web of Science ®Google Scholar
• Henquet C, Rosa A, Delespaul P, Papiol S, Fananas L, van Os J, Myin-Germeys I. COMT ValMet moderation of cannabis-induced psychosis: a momentary assessment study of ‘switching on’ hallucinations in the flow of daily life. Acta Psychiatr Scand 2009;119:156–160.
   PubMed Web of Science ®Google Scholar
• Zammit S, Spurlock G, Williams H, Norton N, Williams N, O’Donovan MC, Owen MJ. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry 2007;191:402–407.
   PubMed Web of Science ®Google Scholar
• Alemany S, Arias B, Fatjo-Vilas M, Villa H, Moya J, Ibanez MI, Ortet G, et al. Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr Scand 2014;129:54–62.
   PubMed Web of Science ®Google Scholar
• Colizzi M, Iyegbe C, Powell J, Ursini G, Porcelli A, Bonvino A, Taurisano P, et al. Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. Schizophr Bull 2015;41:1171–1182.
   PubMed Web of Science ®Google Scholar
• van Winkel R. Genetic Risk and Outcome in Psychosis (GROUP) Investigators. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 2011;68:148–157.
   Google Scholar
• Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 2012;72:811–816.
   PubMed Web of Science ®Google Scholar
• Decoster J, van Os J, Kenis G, Henquet C, Peuskens J, De Hert M, van Winkel R. Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet 2011;156B:363–369.
   PubMed Web of Science ®Google Scholar
• Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006;60:132–140.
   PubMed Web of Science ®Google Scholar
• Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008;9:437–452.
   PubMed Web of Science ®Google Scholar
• Stadelmann AM, Roser P, Arning L, Gallinat J, Epplen JT, Juckel G. Acute effects of delta9-tetrahydrocannabinol on the auditory evoked mismatch negativity are modulated by the NRG1 gene. Pharmacopsychiatry 2010;43:194–195.
   PubMed Web of Science ®Google Scholar
• Power RA, Verweij KJ, Zuhair M, Montgomery GW, Henders AK, Heath AC, Madden PA, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry 2014;19:1201–1204.
   PubMed Web of Science ®Google Scholar